Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmunityBio, Inc. on March 19, 2025, covering events occurring on March 13, 2025. The filing addresses a change in the Company's independent registered public accounting firm.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance regarding the external auditor.
Material Changes
- Dismissal of Auditor: On March 13, 2025, the Audit Committee dismissed Ernst & Young LLP (EY) as the independent registered public accounting firm.
- Reason for Dismissal: The dismissal was not related to any disagreements on accounting principles, financial statement disclosure, or auditing scope. EY's reports for fiscal years 2023 and 2024 were unqualified.
- Appointment of New Auditor: On March 13, 2025, the Audit Committee engaged Deloitte & Touche LLP (Deloitte) as the new independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed is the transition of audit responsibilities. The Company confirmed that no "reportable events" occurred during the tenure of EY or the interim period leading up to the change. EY provided a letter dated March 17, 2025, agreeing with the statements made in this report.
Key Facts for Investor Verification
- Verify the effective date of the new audit engagement with Deloitte & Touche LLP.
- Review the letter from Ernst & Young LLP (Exhibit 16.1) to confirm their concurrence with the dismissal reasons.
- Monitor future filings for the first financial statements audited by Deloitte for the fiscal year ending December 31, 2025.
- Confirm that no undisclosed disagreements existed between the Company and EY regarding accounting practices.